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Background
Vaccine safety authorities such as the US Food and Drug Administration (FDA) and the Australian 
National Centre for Immunisation Research & Surveillance (NCIRS) use studies such as Mitkus et 
al.1 and Jefferson et al.2 to claim that aluminum adjuvants in vaccines are safe. 
Discussion
Mitkus et al.1 provide the following description of the effect of aluminum adjuvants on the immune 
system.
“Aluminum adjuvants are important components of vaccines, since they stimulate the immune system 
to respond more effectively to protein or polysaccharide antigens that have been adsorbed to the surface
of insoluble aluminum particles. Specifically, these coated particles are phagocytized by cells of the 
innate immune system (e.g., macrophages) and activate intracytoplasmic sensors of pathogen-
associated molecular patterns located within the cells, such as the nucleotide-binding domain leucine-
rich repeat-containing family of sensors ([6]; Schroder and Tschopp [30]). The functional consequence 
of activation of this intracellular system is the activation of certain enzymatic caspases that cleave pro-
interleukin (IL)-1β to interleukin (IL)-1β. The secretion of the mature cytokine, IL-1β, leads to an 
inflammatory reaction and a downstream Th2-dependent antibody response [7], which amplify the 
immune response to the antigen. Adjuvanted aluminum, therefore, plays a vital role in facilitating the 
response that underlies the immunoprotection afforded by vaccines.”
The rest of the Mitkus et al. review focuses on body burden of aluminum after it is absorbed from the 
muscle into the blood. They completely ignored any negative immunological effects that aluminum 
can have while it is still in the muscle (following intramuscular vaccine administration).
The quoted paragraph above assumes that the only proteins in the vaccine are viral/bacterial target 
proteins required for immunoprotection. In that case, as they state, the stimulation by aluminum plays a
vital role in generating immunoprotection.
But obviously, vaccines contain numerous other proteins including food proteins (ovalbumin, milk, soy,
yeast, oils from sesame, peanut, fish etc.)3,4, culture medium cell proteins (Vero monkey kidney cell 
proteins, calf serum proteins, WI38/MRC5 fibroblast cell proteins, chick embryo cell culture proteins 
etc.)3, non-target viral/bacterial proteins5, that are also adsorbed on to the surface of insoluble 
aluminum particles. As they state then, aluminum adjuvants stimulate the immune system to respond 
more effectively to ALL these proteins as well. The result is off-target immune responses that includes 
synthesis of antibodies against any and all of these proteins as well as cell mediated immune responses.
The result of such a response of course includes food allergy6–9, asthma10, autism11,12 and autoimmune 
diseases13,14.
How can they perform a safety assessment of aluminum in vaccines while completely ignoring this 
immunological effect?
Jefferson et al.2 reviewed eight studies (listed in Table 2 of Jefferson et al.) on the effect of aluminum 
adjuvants. Any vaccine will need about 3-4 weeks to take effect. That's how long it takes for the 
immune system to develop the appropriate immune response and antibodies. For this reason, vaccine 
effectiveness investigators wait at least one month post vaccination to assess effectiveness.15 Aluminum
compounds are of course an immunological adjuvant in vaccines.16 So their immunological effect 
(positive or negative) can only be assessed, if the follow-up period is greater than 4 weeks. Only two 
out of eight studies in Jefferson et al. had a follow up period of >4 weeks. So rest of the studies they 
included were useless to assess immunological safety of aluminum adjuvants. Even those two studies 
ignored immune disorders such as allergies, asthma, autism or autoimmunity. As previously described, 
all these immune disorders can be initiated by IgE mediated allergy11 or the Th2 response, which 
aluminum adjuvants are known to produce.1,17So not only were the original studies flawed, Jefferson et 
al. made the mistake of including these flawed studies in their analysis.
To really evaluate the safety of aluminum salts in vaccines, one would have to account for all 
known/potential immunological mechanisms involved with aluminum adjuvants. What are the potential
negative outcomes due to that mechanism? What tests are needed to check for those outcomes? Would 
the outcomes be overt disease or will they be sub-clinical effects for years? This would determine 
follow-up times and decision on serological examination. For example: to assess if aluminum may be 
increasing the risk of sensitization to cow's milk proteins contaminating the vaccine, one would not 
only have to wait for 4 weeks after vaccination, but also challenge the patient with cow's milk, pre and 
post vaccination, to assess the impact. Similarly, to check if aluminum induced an autoimmune disease 
that may only show up years later, one would have to perform autoimmune serology pre and post-
vaccination checking for changes in autoantibody levels, as suggested by Wraith et al.18 Nobody 
performs such studies. Why?
In fact, vaccine makers seem to go out of the way to obscure the adverse effects of aluminum adjuvants
by injecting aluminum adjuvant into control subjects during vaccine clinical safety trials.15
Given this situation, the Jefferson et al. conclusion “Despite a lack of good-quality evidence we do not 
recommend that any further research on this topic is undertaken.” is inexplicable and raises serious 
questions about the manner in which vaccine safety investigations are conducted.
Evidence of aluminum adjuvant dangers
Morris et al.19 have called for the elimination of aluminum adjuvant in vaccines.
Prof. Franco Celada, Dept. of Pathology, NYU School of Medicine, called for safety studies of 
aluminum adjuvant induced innate immune system activation (personal email communication, Oct 
2017) in the context of low affinity self reactive (LASR) T cell mediated autoimmune 
diseases13,14 caused by animal protein contaminated vaccines.
Anders et al.20 have called for the re-evaluation of aluminum adjuvants in vaccines due to its role in 
boosting IgE mediated responses. In other words, a Th2-dependent antibody response as described by 
Mitkus et al.1 and Terhune et al.21
Terhune et al.22 further link Treg dysregulation in atopic disease to aluminum adjuvants.
Shoenfeld et al.23 describe aluminum adjuvant induced autoimmunity.
Aluminum immunotoxicity followed by neurotoxicity in autism
Many vaccines contain casein or casamino acids of bovine milk origin and are thus contaminated with 
all bovine milk proteins.3,24 One such protein is the bovine folate receptor (FR) protein.25 Such 
aluminum adjuvanted, bovine FR protein contaminated vaccines can cause IgE mediated sensitization 
to the FR protein (aluminum adjuvant induced Th2 response1).4,6,10 Since FR concentration in bovine 
milk is low, the patient can still consume bovine milk without developing an allergic reaction.25,26 It has 
been shown that consuming milk when sensitized (via an oral immunotherapy protocol, for example) 
will result in the synthesis of IgG4 antibodies specific to milk proteins.8 In this case, bovine milk 
consumption causes FR specific IgG4 synthesis. These IgG4 antibodies cross-react with human folate 
receptors. Human and bovine FR proteins have 90% amino acid sequence homology.27 IgG4 specific to 
FR is the main antibody involved in binding/blocking folate receptors in the choroid plexus, blocking 
folate uptake to the brain.27 This results in cerebral folate deficiency and autism.28 Folate deficiency in 
turn, results in aluminum accumulation in the brain and aluminum induced neurotoxicity.29–31 The 
source of the aluminum could of course be the diet, pollutant inhalation and aluminum adjuvanted 
vaccines. Mold et al.32 have demonstrated such aluminum accumulation in human autistic brain tissue.
Conclusion
The FDA makes a mockery of science by comparing aluminum in vaccines to dietary aluminum.33 In 
that case, we should be drinking our aluminum adjuvanted vaccines, instead of intramuscular injection.
The FDA’s Mitkus et al. study is titled “Updated aluminum pharmacokinetics following infant 
exposures through diet and vaccination.”. They studied pharmacokinetics - how aluminum moves 
through the body. While aluminum pharmacokinetics related safety needs to be understood, they cannot
ignore aluminum adjuvant immunotoxicity, if they were really interested in vaccine aluminum adjuvant
safety. If the FDA is incapable of even determining the appropriate lines of safety investigations 
required, how can they be in charge of vaccine safety? How can we expect vaccines approved by the 
FDA to be safe?
Safety needs engineering not tinkering
For decades, vaccinologists have been reluctant to understand the immunological mechanism of how
vaccines work, fail or hurt the body. Pulendran et al.34 write:
“Despite their success, one of the great iro-nies of vaccinology is that the vast majority of vaccines 
have been developed empirically, with little or no understanding of the immunological mechanisms by 
which they induce protective immunity. However, the failure to develop vaccines against global 
pandemics such as infection with human immunodeficiency virus (HIV) despite decades of effort has 
underscored the need to understand the immunological mechanisms by which vaccines confer 
protective immunity.” 
Mojsilovic16:
"Some of the first adjuvants discovered back then, on empirical basis of trial and error, are still in
widespread use today, but only recently some light on the molecular mechanisms of their action has
been shed."
There seems to be little interest among vaccine developers and regulators in understanding the 
mechanisms of immunoprotection or immunotoxicity of vaccines and adjuvants. This is no way to 
build a safety critical product, centuries after its invention. 
Since the immunological mechanisms of vaccines are not understood, one would expect that vaccine 
makers and regulators will be extremely cautious about making vaccine safety claims. One would 
expect that they will thoroughly investigate even the slightest indication of vaccine-induced adverse 
events. Instead, we find vaccine makers and regulators collude to hide vaccine safety problems. The 
Shingrix vaccine was recently approved after an inadequate safety evaluation.35 The FDA briefing 
document (Sep 2017) describes serious adverse events (SAEs) including supraventricular tachycardia 
following Shingrix vaccination in clinical studies. The Shingrix vaccine package insert (revised 
10/2017)36 has no reference to supraventricular tachycardia at all.
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